scholarly journals Primary Hyperparathyroidism and Celiac Disease: A Population-Based Cohort Study

2012 ◽  
Vol 97 (3) ◽  
pp. 897-904 ◽  
Author(s):  
Jonas F. Ludvigsson ◽  
Olle Kämpe ◽  
Benjamin Lebwohl ◽  
Peter H. R. Green ◽  
Shonni J. Silverberg ◽  
...  
Keyword(s):  
Cohort Study ◽  
Celiac Disease ◽  
Confidence Interval ◽  
Primary Hyperparathyroidism ◽  
Absolute Risk ◽  
Excess Risk ◽  
Endocrine Disorders ◽  
Increased Risk ◽  
The Absolute

Context: Celiac disease (CD) has been linked to several endocrine disorders, including type 1 diabetes and thyroid disorders, but little is known regarding its association to primary hyperparathyroidism (PHPT). Objective: The aim of the study was to examine the risk of PHPT in patients with CD. Design and Setting: We conducted a two-group exposure-matched nonconcurrent cohort study in Sweden. A Cox regression model estimated hazard ratios (HR) for PHPT. Participants: We identified 17,121 adult patients with CD who were diagnosed through biopsy reports (Marsh 3, villous atrophy) from all 28 pathology departments in Sweden. Biopsies were performed in 1969–2008, and biopsy report data were collected in 2006–2008. Statistics Sweden then identified 85,166 reference individuals matched with the CD patients for age, sex, calendar period, and county. Main Outcome Measure: PHPT was measured according to the Swedish national registers on inpatient care, outpatient care, day surgery, and cancer. Results: During follow-up, 68 patients with CD and 172 reference individuals developed PHPT (HR = 1.91; 95% confidence interval = 1.44–2.52). The absolute risk of PHPT was 42/100,000 person-years with an excess risk of 20/100,000 person-years. The risk increase for PHPT only occurred in the first 5 yr of follow-up; after that, HR were close to 1 (HR = 1.07; 95% confidence interval = 0.70–1.66). Conclusions: CD patients are at increased risk of PHPT, but the absolute risk is small, and the excess risk disappeared after more than 5 yr of follow-up.

scholarly journals SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study

BMJ ◽  
2021 ◽  
pp. e068665
Author(s):  
Anders Husby ◽  
Jørgen Vinsløv Hansen ◽  
Emil Fosbøl ◽  
Emilia Myrup Thiesson ◽  
Morten Madsen ◽  
...  
Keyword(s):  
Cohort Study ◽  
Confidence Interval ◽  
Population Based ◽  
Hazard Ratio ◽  
Adjusted Hazard Ratio ◽  
Absolute Rate ◽  
Hazard Ratios ◽  
Increased Risk ◽  
The Absolute

AbstractObjectiveTo investigate the association between SARS-CoV-2 vaccination and myocarditis or myopericarditis.DesignPopulation based cohort study.SettingDenmark.Participants4 931 775 individuals aged 12 years or older, followed from 1 October 2020 to 5 October 2021.Main outcome measuresThe primary outcome, myocarditis or myopericarditis, was defined as a combination of a hospital diagnosis of myocarditis or pericarditis, increased troponin levels, and a hospital stay lasting more than 24 hours. Follow-up time before vaccination was compared with follow-up time 0-28 days from the day of vaccination for both first and second doses, using Cox proportional hazards regression with age as an underlying timescale to estimate hazard ratios adjusted for sex, comorbidities, and other potential confounders.ResultsDuring follow-up, 269 participants developed myocarditis or myopericarditis, of whom 108 (40%) were 12-39 years old and 196 (73%) were male. Of 3 482 295 individuals vaccinated with BNT162b2 (Pfizer-BioNTech), 48 developed myocarditis or myopericarditis within 28 days from the vaccination date compared with unvaccinated individuals (adjusted hazard ratio 1.34 (95% confidence interval 0.90 to 2.00); absolute rate 1.4 per 100 000 vaccinated individuals within 28 days of vaccination (95% confidence interval 1.0 to 1.8)). Adjusted hazard ratios among female participants only and male participants only were 3.73 (1.82 to 7.65) and 0.82 (0.50 to 1.34), respectively, with corresponding absolute rates of 1.3 (0.8 to 1.9) and 1.5 (1.0 to 2.2) per 100 000 vaccinated individuals within 28 days of vaccination, respectively. The adjusted hazard ratio among 12-39 year olds was 1.48 (0.74 to 2.98) and the absolute rate was 1.6 (1.0 to 2.6) per 100 000 vaccinated individuals within 28 days of vaccination. Among 498 814 individuals vaccinated with mRNA-1273 (Moderna), 21 developed myocarditis or myopericarditis within 28 days from vaccination date (adjusted hazard ratio 3.92 (2.30 to 6.68); absolute rate 4.2 per 100 000 vaccinated individuals within 28 days of vaccination (2.6 to 6.4)). Adjusted hazard ratios among women only and men only were 6.33 (2.11 to 18.96) and 3.22 (1.75 to 5.93), respectively, with corresponding absolute rates of 2.0 (0.7 to 4.8) and 6.3 (3.6 to 10.2) per 100 000 vaccinated individuals within 28 days of vaccination, respectively. The adjusted hazard ratio among 12-39 year olds was 5.24 (2.47 to 11.12) and the absolute rate was 5.7 (3.3 to 9.3) per 100 000 vaccinated individuals within 28 days of vaccination.ConclusionsVaccination with mRNA-1273 was associated with a significantly increased risk of myocarditis or myopericarditis in the Danish population, primarily driven by an increased risk among individuals aged 12-39 years, while BNT162b2 vaccination was only associated with a significantly increased risk among women. However, the absolute rate of myocarditis or myopericarditis after SARS-CoV-2 mRNA vaccination was low, even in younger age groups. The benefits of SARS-CoV-2 mRNA vaccination should be taken into account when interpreting these findings. Larger multinational studies are needed to further investigate the risks of myocarditis or myopericarditis after vaccination within smaller subgroups.

scholarly journals Acute urinary retention and risk of cancer: population based Danish cohort study

BMJ ◽  
2021 ◽  
pp. n2305
Author(s):  
Maria Bisgaard Bengtsen ◽  
Dóra Körmendiné Farkas ◽  
Michael Borre ◽  
Henrik Toft Sørensen ◽  
Mette Nørgaard
Keyword(s):  
Prostate Cancer ◽  
Cohort Study ◽  
Urinary Retention ◽  
Acute Urinary Retention ◽  
Absolute Risk ◽  
Population Based ◽  
Excess Risk ◽  
Tract Cancer ◽  
Urinary Tract Cancer

Abstract Objective To examine the risk of urogenital, colorectal, and neurological cancers after a first diagnosis of acute urinary retention. Design Nationwide population based cohort study. Setting All hospitals in Denmark. Participants 75 983 patients aged 50 years or older with a first hospital admission for acute urinary retention during 1995-2017. Main outcome measures Absolute risk of urogenital, colorectal, and neurological cancer and excess risk of these cancers among patients with acute urinary retention compared with the general population. Results The absolute risk of prostate cancer after a first diagnosis of acute urinary retention was 5.1% (n=3198) at three months, 6.7% (n=4233) at one year, and 8.5% (n=5217) at five years. Within three months of follow-up, 218 excess cases of prostate cancer per 1000 person years were detected. An additional 21 excess cases per 1000 person years were detected during three to less than 12 months of follow-up, but beyond 12 months the excess risk was negligible. Within three months of follow-up the excess risk for urinary tract cancer was 56 per 1000 person years, for genital cancer in women was 24 per 1000 person years, for colorectal cancer was 12 per 1000 person years, and for neurological cancer was 2 per 1000 person years. For most of the studied cancers, the excess risk was confined to within three months of follow-up, but the risk of prostate and urinary tract cancer remained increased during three to less than 12 months of follow-up. In women, an excess risk of invasive bladder cancer persisted for several years. Conclusions Acute urinary retention might be a clinical marker for occult urogenital, colorectal, and neurological cancers. Occult cancer should possibly be considered in patients aged 50 years or older presenting with acute urinary retention and no obvious underlying cause.

scholarly journals Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study

2019 ◽  
Vol 30 (5) ◽  
pp. 866-876 ◽  
Author(s):  
Simon Jarrick ◽  
Sigrid Lundberg ◽  
Adina Welander ◽  
Juan-Jesus Carrero ◽  
Jonas Höijer ◽  
...  
Keyword(s):  
Cohort Study ◽  
Life Expectancy ◽  
Iga Nephropathy ◽  
Absolute Risk ◽  
Reference Population ◽  
Population Based ◽  
Increased Risk ◽  
Using Data ◽  
Increases In Risk

BackgroundThe clinical course of IgA nephropathy (IgAN) varies from asymptomatic nonprogressive to aggressive disease, with up to one in four patients manifesting ESRD within 20 years of diagnosis. Although some studies have suggested that mortality appears to be increased in IgAN, such studies lacked matched controls and did not report absolute risk.MethodsWe conducted a population-based cohort study in Sweden, involving patients with biopsy-verified IgAN diagnosed in 1974–2011; main outcome measures were death and ESRD. Using data from three national registers, we linked 3622 patients with IgAN with 18,041 matched controls; we also conducted a sibling analysis using 2773 patients with IgAN with 6210 siblings and a spousal analysis that included 2234 pairs.ResultsDuring a median follow-up of 13.6 years, 577 (1.1%) patients with IgAN died (10.67 per 1000 person-years) compared with 2066 deaths (0.7%) in the reference population during a median follow-up of 14.1 years (7.45 per 1000 person-years). This corresponded to a 1.53-fold increased risk and an absolute excess mortality of 3.23 per 1000 person-years (equaling one extra death per 310 person-years) and a 6-year reduction in median life expectancy. Similar increases in risk were seen in comparisons with siblings and spouses. IgAN was associated with one extra case of ESRD per 54 person-years. Mortality preceding ESRD was not significantly increased compared with controls, spouses, or siblings. Overall mortality did not differ significantly between patients with IgAN-associated ESRD and patients with ESRD from other causes.ConclusionsPatients with IgAN have an increased mortality compared with matched controls, with one extra death per 310 person-years and a 6-year reduction in life expectancy.

scholarly journals First-time postmenopausal bleeding as a clinical marker of long-term cancer risk: A Danish Nationwide Cohort Study

2019 ◽  
Vol 122 (3) ◽  
pp. 445-451 ◽  
Author(s):  
Maria B. Bengtsen ◽  
Katalin Veres ◽  
Mette Nørgaard
Keyword(s):  
Bladder Cancer ◽  
Endometrial Cancer ◽  
Cohort Study ◽  
Absolute Risk ◽  
Population Based ◽  
Postmenopausal Bleeding ◽  
The Absolute ◽  
Risk Of Cancer

Abstract Background Data on long-term risk of cancer after a postmenopausal bleeding diagnosis are sparse. Methods We used Danish medical registries to conduct a population-based cohort study of women with a first hospital-diagnosed postmenopausal bleeding during 1995–2013. We computed the absolute risk of cancer and the standardised incidence ratio (SIR) comparing the observed cancer incidence with that expected in the general population. Results Among 43,756 women with postmenopausal bleeding, the absolute 1- and 5-year risk of endometrial cancer were 4.66% and 5.18%, respectively. The SIR of endometrial cancer was elevated during 0–3 months (SIR = 330.36 (95% CI: 315.43–345.81)), 3–12 months (SIR = 11.39 (95% CI: 9.79–13.17)), 1–5 years (SIR = 2.55 (95% CI: 2.19–2.94)) and >5 years of follow-up (SIR = 1.63 (95% CI: 1.40–1.90)). All selected gynaecological and urological, gastrointestinal and haematological cancers had elevated 0–3 months SIRs. Beyond 1 year of follow-up the SIRs of ovarian and bladder cancer remained elevated with a 1–5-year SIR of 2.15 (95% CI: 1.71–2.65) and 1.45 (95% CI: 1.14–1.80), respectively. Conclusions In the Danish population, women with a first hospital-diagnosed postmenopausal bleeding have an increased 0–3 months risk of gynaecological, urological, gastrointestinal and haematological cancers. The SIR of endometrial, ovarian and bladder cancer remained elevated for several years.

scholarly journals Dose Dependency of Iatrogenic Glucocorticoid Excess and Adrenal Insufficiency and Mortality: A Cohort Study in England

2019 ◽  
Vol 104 (9) ◽  
pp. 3757-3767 ◽  
Author(s):  
Teumzghi F Mebrahtu ◽  
Ann W Morgan ◽  
Adam Keeley ◽  
Paul D Baxter ◽  
Paul M Stewart ◽  
...  
Keyword(s):  
Cohort Study ◽  
Adverse Events ◽  
Adrenal Insufficiency ◽  
Cushing Syndrome ◽  
Inflammatory Diseases ◽  
Absolute Risk ◽  
Incidence Rates ◽  
Hazard Ratios ◽  
Increased Risk

Abstract Context Adrenal insufficiency and Cushing syndrome are known adverse events of glucocorticoids. However, no population estimates of dose-related risks are available. Objective To investigate dose-related risks of adrenal dysfunction and death in adults with six chronic inflammatory diseases treated with oral glucocorticoids. Design and setting Retrospective, record-linkage, open-cohort study spanning primary and hospital care in England. Patients A total of 70,638 oral glucocorticoid users and 41,166 nonusers aged ≥18 years registered in 389 practices in 1998 to 2017. Main outcome measures Incidence rates and hazard ratios (HRs) of diagnosed adrenal dysfunction and death. Results During a median follow-up of 5.5 years, 183 patients had glucocorticoid-induced adrenal insufficiency and 248 had glucocorticoid-induced Cushing syndrome. A total of 22,317 (31.6%) and 7544 (18.3%) deaths occurred among glucocorticoid users and nonusers, respectively. The incidence of all outcomes increased with higher current daily and cumulative doses. For adrenal insufficiency, the increases in HRs were 1.07 (95% CI: 1.04 to 1.09) for every increase of 5 mg per day and 2.25 (95% CI: 2.15 to 2.35) per 1000 mg of cumulative prednisolone-equivalent dose over the past year. The respective increases in HRs for Cushing syndrome were 1.09 (95% CI: 1.08 to 1.11) and 2.31 (95% CI: 2.23 to 2.40) and for mortality 1.26 (95% CI: 2.24 to 1.28) and 2.05 (95% CI: 2.04 to 2.06). Conclusion We report a high glucocorticoid dose-dependent increased risk of adrenal adverse events and death. The low observed absolute risk of adrenal insufficiency highlights a potential lack of awareness and a need for increased physician and patient education about the risks of adrenal dysfunction induced by glucocorticoids.

scholarly journals Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study

2009 ◽  
Vol 69 (3) ◽  
pp. 490-494 ◽  
Author(s):  
W H Bos ◽  
G J Wolbink ◽  
M Boers ◽  
G J Tijhuis ◽  
N de Vries ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cohort Study ◽  
Confidence Interval ◽  
Cox Regression ◽  
Shared Epitope ◽  
Hazard Ratios ◽  
Increased Risk ◽  
Clinical Arthritis ◽  
Citrullinated Protein

BackgroundAnti-citrullinated protein antibodies (ACPA) are associated with increased risk for rheumatoid arthritis.ObjectiveTo investigate the effect of the presence and levels of ACPA on arthritis development in patients with arthralgia.MethodsPatients with arthralgia positive for ACPA or IgM rheumatoid factor (IgM-RF) were tested for the shared epitope (SE) and were prospectively followed up for at least 12 months. Absence of clinical arthritis at inclusion and arthritis development during follow-up were independently confirmed by two investigators. Cox regression hazard analyses were used to calculate hazard ratios (HRs) for arthritis development.Results147 patients with arthralgia were included (50 ACPA positive, 52 IgM-RF positive and 45 positive for both antibodies). After a median follow-up of 28 months (interquartile range (IQR) 19–39), 29 patients developed arthritis in a median of 4 (IQR 3–6) joints and 26 (90%) of these were ACPA positive. The presence of ACPA (HR = 6.0; 95% confidence interval (95% CI) 1.8 to 19.8; p = 0.004), but not of IgM-RF (HR = 1.4, 95% CI 0.6 to 3.1) nor the SE (HR = 1.5, 95% CI 0.7 to 3.0), was associated with arthritis development. Within the group of ACPA-positive patients, the risk for arthritis was enhanced by the presence of IgM-RF (HR = 3.0; 95% CI 1.4 to 6.9; p = 0.01) and high ACPA levels (HR = 1.7; 95% CI 1.1 to 2.5; p = 0.008), but not the SE (HR = 1.0; 95% CI 0.5 to 2.1; p = 1.0).ConclusionIn patients with arthralgia the presence of ACPA (but not of IgM-RF or SE) predicts arthritis development. The risk in ACPA-positive patients may be further increased by the concomitant presence of IgM-RF or high levels of ACPA.

scholarly journals Venous Thromboembolism and Risk of Cancer in Patients with Dementia: A Danish Population-Based Cohort Study

2021 ◽  
pp. 1-13
Author(s):  
Cecilia H. Fuglsang ◽  
David Nagy ◽  
Frederikke S. Troelsen ◽  
Dora K. Farkas ◽  
Victor W. Henderson ◽  
...  
Keyword(s):  
Cohort Study ◽  
Venous Thromboembolism ◽  
General Population ◽  
Confidence Interval ◽  
Absolute Risk ◽  
Population Based ◽  
First Year ◽  
People With Dementia ◽  
Increased Risk ◽  
Risk Of Cancer

Background: Venous thromboembolism (VTE) may be the first manifestation of occult cancer. Dementia has been linked to reduced cancer risk. Objective: We examined the risk of cancer following VTE in people with dementia in comparison to the risk in the general population. Methods: We conducted a population-based Danish registry-based cohort study following patients with a first-time VTE and a previous or concurrent diagnosis of dementia during the period 1 April 1996 –31 December 2017. We followed the study participants from date of VTE until diagnosis of cancer, death, emigration, or end of study period, whichever came first. The absolute risk of cancer within one year after VTE was computed, treating death as a competing risk. We calculated gender, age, and calendar-period standardized incidence ratios (SIRs) of cancer based on national cancer rates. Results: We followed 3,552 people with dementia and VTE for a median of 1.3 years. Within the first year after VTE, they had a 90%increased risk of cancer in comparison with the general population [SIR: 1.9 (95%confidence interval: 1.6–2.4)]. During subsequent follow-up years, the SIR fell to 0.7 (95%confidence interval: 0.5–0.8). Findings for Alzheimer’s disease and VTE were similar. Conclusion: People with dementia have an increased risk of a cancer diagnosis during the first year following VTE, perhaps related to increased surveillance, and a lower risk thereafter. Overall risk is similar to that of the general population.

scholarly journals Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study

BMJ ◽  
2021 ◽  
pp. n107 ◽  
Author(s):  
Niklas Worm Andersson ◽  
Rasmus Huan Olsen ◽  
Jon Trærup Andersen
Keyword(s):  
Cohort Study ◽  
Relative Risk ◽  
Confidence Interval ◽  
Birth Defects ◽  
Absolute Risk ◽  
Risk Difference ◽  
Relative Risk Ratio ◽  
Macrolide Antibiotics ◽  
Increased Risk ◽  
In Pregnancy

Abstract Objective To examine the association between the use of macrolide antibiotics in pregnancy and the risk of major birth defects. Design Nationwide, register based cohort study. Setting Denmark, 1997-2016. Participants Of 1 192 539 live birth pregnancies, pregnancies during which macrolides had been used (13 019) were compared with those during which penicillin (that is, phenoxymethylpenicillin) had been used (matched in a 1:1 ratio on propensity scores). Other comparative groups were pregnancies when macrolides had been used recently but before pregnancy (matched 1:1) and pregnancies where no antibiotics had been used (matched 1:4). Main outcome measures Association with an outcome of any major birth defect and specific subgroups of birth defects were assessed by relative risk ratios and absolute risk differences. Results In matched comparisons, 457 infants were born with major birth defects to women who had used macrolides during pregnancy (35.1 per 1000 pregnancies) compared with 481 infants (37.0 per 1000 pregnancies) to women who had used penicillin (relative risk ratio 0.95; 95% confidence interval 0.84 to 1.08), corresponding to an absolute risk difference of −1.8 (95% confidence interval −6.4 to 2.7) per 1000 pregnancies. The risk of major birth defects was not significantly increased for women who had used macrolides during pregnancy compared with those who had used macrolides recently but before becoming pregnant (relative risk ratio 1.00 (95% confidence interval 0.88 to 1.14); absolute risk difference −0.1 (95% confidence interval −4.8 to 4.7) per 1000 pregnancies) or compared with women who did not use any antibiotics (1.05 (0.95 to 1.17); 1.8 (−1.7 to 5.3) per 1000 pregnancies). For all three comparative group analyses and in the analyses of use of individual macrolides, no significant increased risk of specific subgroups of birth defects associated with the use of macrolides was found. Conclusions In this nationwide cohort study, the use of macrolide antibiotics in pregnancy was not associated with an increased risk of major birth defects. Analyses of the associated risk of 12 specific subgroups of birth defects with the use of macrolides in pregnancy were not significant.

Sign in / Sign up

Export Citation Format

Share Document